B6CB-Tg(CD2-NPM/ALK)4Sudt/H
| Status | Available to order |
| EMMA ID | EM:01727 |
| Citation information | RRID:IMSR_EM:01727 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6CB-Tg(CD2-NPM/ALK)4Sudt/H |
| Alternative name | CD2/NPM-ALK |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(CD2-NPM/ALK)4Sudt |
| Gene/Transgene symbol | Tg(CD2-NPM/ALK)4Sudt |
Information from provider
| Provider | Suzanne Turner |
| Provider affiliation | The Babraham Institute, Babraham, Cambridge, CB2 4PB |
| Genetic information | The oncogenic nucleophosmin/anaplastic lymphoma tyrosine kinase (NPM-ALK; associated with anaplastic large cell lymphoma) is expressed in the T lineage of these transgenic mice under the control of the CD2 promoter. Approx. 10% of these mice develop lymphoid malignancies at ages ranging from 9 months to over 2 years. The tumours are of various phenotypes including thymic, splenic and hepatic. |
| Phenotypic information | Approx. 10% of mice develop tumours of haemopoietic organs within 2 years of age. |
| References |
|
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Literature references
- CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.;Turner Suzanne D, Merz Hartmut, Yeung Debra, Alexander Denis R, ;2006;Anticancer research;26;3275-9; 17094440